Metolazone – switching to Xaqua®
Xaqua® brand is licensed and should be used first line. All metolazone products should be prescribed by brand name and must not be switched without careful dose titration, due to the differences in bioavailability...
Author: Alex
New Tocilizumab PIL in Welsh
There is a new patient information leaflet in Welsh on tocilizumab treatment of COVID-19.
New Q&A – Is there a role for inhaled epoprostenol, inhaled nitric oxide or sildenafil to treat secondary pulmonary hypertension and hypoxaemia in ICU patients with acute respiratory distress syndrome?
There is a new UKMi Q&A – Is there a role for inhaled epoprostenol, inhaled nitric oxide or sildenafil to treat secondary pulmonary hypertension and hypoxaemia in ICU patients with acute respiratory distress syndrome?
Updated Q&A – How should crusted and difficult-to-treat scabies be managed?
There is an update to the UKMi Q&A: How should crusted and other forms of difficult-to-treat scabies be managed?
Updated Q&A – Which commonly used nebuliser solutions are compatible?
There is an update to the UKMi Q&A for Which commonly used nebuliser solutions are compatible?
Updated Q&A – Cannabidiol oil – potential adverse effects
There is an updated UKMi Q&A: Cannabidiol-oil-potential-adverse-effects
Updated Q&A – What is the most suitable treatment for acne in a patient with acute porphyria?
There is an updated UKMi Q&A – What is the most suitable treatment for acne in a patient with acute porphyria?
Updated Q&A – What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors (SSRIs)?
There is an updated UKMi Q&A – What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors (SSRIs)?
Updated Q&A – Cannabidiol oil – potential adverse effects
There is an updated UKMi Q&A – Cannabidiol oil – potential adverse effects
Updated Q&A – Are topical medicines safe in people with porphyria?
There is an updated UKMI Q&A – Are topical medicines safe in people with porphyria?
